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ABSTRACT:  
BACKGROUND: Pelvic and paraaortic lymphadenectomy are recommended for women with high-
intermediate, high-risk and advanced endometrial cancer (EC). Lymphadenectomy is less frequently 
performed in elderly patients than in younger patients. We examined the survival of elderly women 
diagnosed with high-risk EC according to whether lymphadenectomy was performed or not. 
METHODS: We selected women over 70 years with high-intermediate risk, high-risk or advanced 
EC from a multicenter retrospective cohort of women diagnosed between 2001 and 2013. 
Multivariate logistic regression models and Cox proportional hazards survival methods for overall 
survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS) were used for 
analyses. 
RESULTS: 71 women had lymphadenectomy and were compared with the 213 who did not. 
Recurrence was similar in both groups (42% vs 33%, respectively, p=0.17) but more deaths were 
reported in the group without lymphadenectomy (38% vs 23%, respectively, p<0.001). There was 
no difference in adjuvant treatment in the two groups (17% vs 27%, respectively, p=0.27). Elderly 
patients without lymphadenectomy had lower 3-year DFS (56% vs 71%, p=0.076), CSS (67% vs 
85%, p<0.001) and OS (50% vs 71% p<0.001). The Cox pr portional hazard models showed 
independently poorer prognosis in women without lymphadenectomy (3.027, 95% CI 1.58-5.81, 
p<0.001), histology type 2 (3.46, 95% CI 1.51-7.97, p=0.003) and lymphovascular space 
involvement (3.47, 95% CI 1.35-8.98, p=0.01) on 3-year CSS. 
CONCLUSION: No lymphadenectomy in elderly patients with high-risk or advanced EC is 
independently associated with poorer prognosis. Elderly patients with EC should benefit from 
lymphadenectomy when indicated.  
 
Key-words: high-risk endometrial cancer; elderly; surgery; lymphadenectomy; cancer-specific 
survival 
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INTRODUCTION   
With the increase in life expectancy, older cancer patients are becoming more numerous (1). 
However, older patients are underrepresented in clinica  trials (2,3), and there is consequently 
somewhat of a gap in the current treatment guidelines for this subgroup of cancer patients (4). 
Elderly patients with cancer are often undertreated both in terms of surgery (5) and adjuvant therapy 
(6). This undertreatment of the elderly is usually because of comorbidities, for fear of complications 
related to surgical or chemotherapy stress (7,8). In the United States, the number of new cases of 
EC per year was 61 380 with 10 920 deaths in 2017 (7th leading cause of cancer related-death in 
women) (9). According to studies, older patients with EC have a poorer prognosis which is due not 
only to more aggressive disease but also undertreatment (10-13).  
According to the European Society for Medical Oncology (ESMO), European Society of 
Gynaecological Oncology (ESGO), and European Society for Radiotherapy and Oncology 
(ESTRO) guidelines, treatments of high-intermediate risk (HIR), high risk (HR) and / or advanced 
EC (14), include surgery (15) with hysterectomy, bilateral salpingo-oophorectomy and pelvic plus 
paraaortic lymphadenectomy (16,17). According to Mariani et al., 22% of patients with HR EC 
have metastatic lymph nodes (51% pelvic and paraaortic, 33% pelvic and 16% paraaortic) (18). 
Although the SEPAL study demonstrated a significant benefit of pelvic plus paraaortic 
lymphadenectomy on survival (19,20), lymphadenectomy was less performed in elderly patients 
with EC, even if lymphadenectomy was recommended by ESMO/ESGO/ESTRO guidelines 
(7,10,12), for fear of complications. Similarly, the older patient is less likely to receive pelvic 
external radiotherapy or chemotherapy which are recommended for patients with HR EC (14) 
(2,21).  Overall then it can be said that elderly patients with EC are undertreated as a result 
incomplete surgical staging and less use of adjuvant therapy, which may explain why they have 
poorer survival rates (7,22). No studies have evaluated the impact of lymphadenectomy in this 
subgroup of elderly patients with HIR, HR or advanced EC. 
The objective of this study is to compare disease-fre  survival (DFS), overall survival (OS), and 
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cancer-specific survival (CSS) in patients aged 70 and over with HIR, HR, or advanced EC 
according to whether they underwent lymphadenectomy r not. 
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MATERIALS AND METHODS: 
Patients:  
We retrospectively analyzed data collected from a database of patients with EC who received 
primary surgical treatment between January 2001 and December 2013. The data were obtained from 
nine institutions in France who maintain EC databases (Tours, Tenon, Dijon, Rennes, Lille, Reims, 
Creteil, Poissy, Jean Verdier Tertiary Hospitals) and from the SENTIENDO trial (23). These 
institutions had high gynecologic oncologic case load, with more than 70 gynecologic oncologic 
surgeries per year for each center. The research protocol was approved by the Institutional Review 
Board of the College National des Gynécologues et Obstétriciens Français (CNGOF) in 2014. 
Patients 70 years of age and older with HIR, HR, or advanced EC, according to the ESMO / 
ESTRO / ESGO (14) criteria were selected. 
The patients were divided into two groups: patients who underwent paraaortic and/or pelvic 
lymphadenectomy versus patients who did not undergo lymphadenectomy. 
Data collection  
All the patients had undergone a preoperative endometrial biopsy and abdominopelvic magnetic 
resonance imaging (MRI) unless contraindicated. 
The demographic and clinical data collected included: age, body mass index (BMI), and 
comorbidities (arterial hypertension, diabetes, menopausal hormone therapy). Surgical data 
(surgical approach, nodal staging), histologic data (subtype, grade and stage based on the 
International Federation of Gynaecology and Obstetrics (FIGO 2009) (24) and adjuvant therapy 
were also collected.  
Histology   
Type 1 tumors consisted of endometrioid adenocarcinomas, villoglandular, tubular, or mucinous 
tumors, with or without an endometrioid component. For these tumors, histologic grade was defined 
by the percentage of undifferentiated component: grade 1 (<5%), grade 2 (6%-50%), and grade 3 
(>50%). The grade was increased by 1 point if nuclear atypia was present. (25). Type 2 tumors were 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
those with at least one serous, clear cell, or carcinosarcoma component. 
Lymph nodes were considered positive when macro- or mic ometastases were present. A tumor was 
considered to have lympho-vascular space invasion (LVSI) when tumor emboli were found within a 
space clearly lined by endothelial cells on a hematoxylin and eosin (H&E)-stained section. 
All the women were classified according to the 2009 FIGO classification after the final  pathologic 
analysis (24). The tumors were classified into recurence risk groups as defined by the ESMO, 
ESGO, and ESTRO guidelines. High-risk cancers include high-intermediate-risk (HIR) 
(endometrioid type 1, grade 1 or 2 tumors with deep  ≥ 50% myometrial invasion and unequivocally 
positive LVSI, and grade 3 tumors with <50% myometrial invasion regardless of LVSI status), 
high-risk (stage IB and grade 3, stage ≥2, type I and type II tumors) and advanced EC. (14)
Treatment and follow-up  
The women underwent primary surgical treatment including at least total hysterectomy with 
bilateral salpingo-oophorectomy, with or without nodal staging (pelvic and paraaortic 
lymphadenectomy) according to the current guidelines and at the surgeon’s discretion based on 
their own patient evaluation (25). According to theFr nch guidelines, pelvic and paraaortic lymph 
node surgical staging is required for HR groups. Adjuvant therapy included vaginal brachytherapy 
(VBT), and/or external beam radiotherapy (EBRT), and/or chemotherapy (CT), and clinical follow-
up. Adjuvant therapy was administered on an individual basis at the discretion of a 
multidisciplinary committee based on the French guidelines (26). 
Clinical follow-up consisted of physical examinations and the use of imaging techniques according 
to the findings.  
Outcome measures   
The main outcome measures were the date of recurrene, date of death, and date of cancer-related 
death. Disease recurrence was diagnosed by biopsy or imaging studies and defined as a relapse 
without differentiating between their local or distan  nature.  
The secondary outcome measures were adjuvant therapy (VBT, EBRT, CT), surgical route 
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(minimally invasive surgery, laparotomy and vaginal surgery) and tumor characteristics (ESMO / 
ESGO / ESTRO group, FIGO stage, histological type, tumor size, LVSI). 
Statistical analysis  
Descriptive parameters are expressed as the mean (± Standard Deviation [SD]) and median [range] 
when indicated. Frequencies are presented as percentages. We compared the demographics and 
medical characteristics of the patients in the two cohorts using Chi-square for categorical variables. 
For continuous variables, we used t-tests. Overall survival time was calculated from the date of 
surgery to death (related or unrelated to cancer) or date of last follow-up for surviving patients, CSS 
as time from the date of surgery to cancer-related death, and DFS as time from the date of surgery 
to cancer recurrence. Women who were alive and without recurrence were censored at the date of 
last follow-up. The Kaplan-Meier method was used to estimate the survival distribution and 
compared with the log-rank test. Effects were expressed as hazard ratios (HRs) with 95% 
confidence intervals (CIs). Cox proportional hazard models included established prognostic factors: 
pathologic type, adjuvant therapies, and nodal statu . A p-value of <0.05 was considered 
statistically significant. Data were managed in an Excel database (Microsoft, Redmond, WA, USA) 
and analysed using R 3.0.2 software, which is availble online. 
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RESULTS   
Characteristics of study population    
During the study period, 1227 women with EC were documented as having received primary 
surgical treatment. 480 women (39%) were ≥70 years old, and 284 (59%) of these women were in 
the high-risk group (HIR, HR or with advanced EC). Of these 284 patients, 213 (75%) underwent 
pelvic ± paraaortic lymphadenectomy and 71 (25%) did not undergo lymphadenectomy. 
The mean age of the entire population was 76.9 years (±5.3). The mean age of the patients without 
lymphadenectomy was 79.6 years (±6) versus 76 years (±4.8) for patients with lymphadenectomy 
(p<0.001).  
The demographic and clinicopathologic characteristics of the entire cohort are reported in Table 1. 
There were no significant differences in comorbidities between the two groups. 
Tumor characteristics   
The tumor characteristics are reported in Table 2. There were no significant differences between the 
two groups concerning histologic type, myometrial invasion, grade or FIGO stage. 
Surgical characteristics and adjuvant treatment  
Surgical procedures are reported in Table 3. In the lymphadenectomy group, 212/213 patients 
(99%) underwent pelvic lymphadenectomy, with an aver g  of 11.9 (±6.19) lymph nodes removed 
and 25/213 patients (12%) had paraaortic lymphadenectomy, with an average of 3.85 (±6.79) lymph 
nodes removed. 44/212 patients (21%) had pelvic lymph node metastasis and 7/25 patients (28%) 
had paraaortic lymph node metastasis. Patients without lymphadenectomy had significantly fewer 
mini-invasive procedures (21% vs 49%, p<0.001). 
Adjuvant treatments are reported in Table 3.  
Survival results  
The mean follow-up of the population was 28.52 months (+/-24.74). The mean follow-up of 
patients with lymphadenectomy and without were 30.29 months (+/-25.64) and 23.21 months (+/-
21.12), respectively (p=0.02). 
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In the whole study population, the 3-year OS, DFS and CSS were 66.8% (95% CI, 60-74.4), 67.4% 
(95% CI, 60.8-74.6) and 81.3% (95% CI, 75.5-87.6), respectively. The univariate analysis of 
survival (DFS, OS and CSS) is reported in Table S1 and Figure 1. The 3-year CSS was significantly 
lower in patients in the without lymphadenectomy group (85.2% (95% CI, 78.9-92.1) vs 67.5% 
(95% CI, 54.8-83.1) (p<0.001)).The multivariate analysis of survival is shown in Table 4. No 
lymphadenectomy was independently associated with a lower 3-year CSS (3.027 (1.58-5.81), 
p<0.001) and 3-year OS (2.374 (1.48-3.81) p<0.001).  
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DISCUSSION   
The present study showed that 25% of patients over 70 years of age with HIR, HR, or advanced EC 
in our cohort did not undergo lymph node assessment. In our study, no lymphadenectomy, type 2 
histology and LVSI correlated in multivariate analysis with poorer CSS and poorer OS. Patients 
without lymphadenectomy also had significantly less adjuvant radiotherapy, contributing to the 
undertreatment of elderly patients who are already under-evaluated surgically (27). Finally, we 
found that patients without lymphadenectomy had less minimally invasive surgery in univariate 
analysis. A lack of knowledge of histologic lymph node status was correlated with poorer survival 
(CSS and OS) in multivariate analysis. 
Few data dealing with HIR, HR or advanced EC and age can be found in literature (7,22), and no 
data focus on the validity of lymphadenectomy in elderly patients with EC. While the role of 
lymphadenectomy remains a subject of passionate debate (29–31), elderly patients have lower rates 
of lymphadenectomy (10,13,28). Todo Y et al. demonstrated that the combination of pelvic and 
paraaortic lymphadenectomy can significantly improve survival in patients with HR EC (19,20). 
Although only patients with HR, HIR or advanced EC were included in our study, the rate of 
paraaortic lymphadenectomy performed was low at around 12%. This low rate could be due to 
changes in the French recommendations (published in 2009 during the data collection period) for 
nodal staging which introduced paraaortic lymphadenectomy for HR, HIR and advanced EC, with 
increased rate of paraaortic lymphadenectomy after 2009.  Secondly, in the Todo patient population, 
the patients were younger with a mean age of 56.2 (+/-9.2) years compared to our elderly cohort 
with a mean age of 76.9 (+/-5.3) years, indicating that elderly patients were not included in the 
Todo Y et al. study (20).  
Minimally invasive surgery tends to be underused in older patients, probably due to possible 
contraindications to laparoscopy (32). However, recent data have demonstrated that minimally 
invasive surgical treatment of EC, robotically assisted or not, is feasible and safe in the elderly 
patient and is superior to open surgery in terms of perioperative procedure results (33), independent 
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of age (34,35). A minimally invasive approach could lead to a higher rate of pelvic or paraaortic 
lymphadenectomy in this age group, as one of the reasons for the reluctance to perform 
lymphadenectomy is the risks associated with xipho-ubic laparotomy. The laparoscopic procedure 
lasts no longer than laparotomy, involves less blood l ss and a shorter hospital stay, causes fewer 
postoperative complications, and results in similar su vival (36,37). The development of robotic 
surgery is going to increase the use of minimally invasive approaches for lymphadenectomy 
(38,39), even in older patients (40).  
In the present study, only 62% of patients with lymphadenectomy and 45% of patients without 
lymphadenectomy had radiotherapy. It is somewhat disappointing to observe that the patients 
without lymphadenectomy had less radiotherapy which is widely recognized to increase survival 
and is generally well tolerated in elderly patients (21,41). Furthermore, we know that radiotherapy 
can be tailored if lymph node staging is performed (42,43). Additionally, only 21% of our 
population had chemotherapy (with no difference betwe n the groups).  
Some limitations to the present analysis should be tak n into account when interpreting the data. As 
for all observational data, there is a potential selection bias: unobserved dimensions of health statu, 
such as performance status, may determine treatment and independently affect survival without 
involving the choice of the patient (44). Driver JA et al., for example, showed that frailty was a 
more robust predictor of DFS and OS than patient age and tumor characteristics in a cohort of older 
women with EC (45). Nevertheless, in present study, except for a higher mean age in the group of 
patients without lymphadenectomy, the number of comorbidities was similar in both groups as were 
all the tumor characteristics. Furthermore, the ratof chemotherapy was similar in both groups (at 
around 21%), indicating that the perception of frailty was probably similar. Nevertheless, similarly 
to other studies, no objective evaluation was used to tailor surgical staging or adjuvant treatment 
according to frailty. Additionally, no attempt was made to replace numerical age by criteria 
evaluating life expectancy: we applied the cutoff of 70 years to define “the elderly patient” as in 
most other studies (46–51). Finally, the primary stength of this study is the use of CSS mortality as 
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opposed to all-cause mortality.  
The sentinel lymph node technique is rarely used in the elderly: in the SENTIENDO study (23), few 
patients included were over 70 years old. Studies have shown good sensitivity for this technique and 
good NPVs by double detection (radioactive tracer and blue dye) or indocyanine green (Se 97.2%, 
99.6% VPN) (52). It is less morbid than complete lymphadenectomy in cases of negative sentinel 
lymph node and allows lymph node staging if there is a discrepancy between the preoperative 
assessment and final histology (53). Finally, the technique can be performed for HR ECs (Se 
95.8%, VPN 98.2) (54,55). The generalization of its use coupled with minimally invasive surgery 
techniques, could promote the practice of complete surgical staging in elderly patients with HR EC 
with minimal morbidity. Knowledge of the lymph node status by the sentinel lymph node technique 
would enable tailoring of the adjuvant treatment for elderly patients and could become the standard 
of treatment for EC in the coming years in elderly patients with EC. 
CONCLUSION 
This French multicenter study shows that a quarter of patients over 70 years with HIR, HR or 
advanced EC have no lymph node assessment. The lack of surgical nodal evaluation in these 
patients is correlated with poorer CSS and OS. Open surgery was also correlated with less frequent 
lymphadenectomy. Gynecologic oncologists should adopt a reproducible attitude in the 
management of EC in the elderly, based not only on preoperative evaluation of the patient’s frailty 
status but also on minimally invasive surgical management. The sentinel lymph node technique 
could be a good option for elderly patients with HIR, HR or advanced EC for whom surgeons are 
reluctant to perform lymphadenectomy because of frailty.  
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Figure 1 : Survival curves : A Relapse-free Survival, B Cancer-specific Survival, C Overall Survival. 
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   Table 1:  Patient characteristics, age ≥ 70ans 
 
 
Characteristics 
 
Population  
n (%)  
N=284 
No lymphadenectomy 
 n (%) 
N = 71 
Lymphadenectomy 
n (%) 
N = 213 
P value 
Age (years), mean (±SD) 76.91 (±5.34) 79.63 (±6.01)                  76 (±4.78) <0.001 
-70-75 
-76-80 
-81-85 
->86 
 
128 (45%) 
91 (32%) 
44 (16%) 
21 (7%) 
20 (28%) 
17 (24%) 
22 (31%) 
12 (17%) 
109 (51%) 
74 (35%) 
21 (10%) 
9 (4%) 
<0.001 
BMI  (kg/m2), mean (±SD) 27.41 (±5.82) 28.44 (±7.30) 27.32 (±5.47) 0.12 
     
Parity, mean (±SD) 2.33 (±1.90) 2.40 (±1.98) 2.31 (±1.88) 0.84 
- 0 22 (8%) 7(10%) 15 (7%) 0.82 
- 1 47 (17%) 10 (14%) 37 (17%)  
- ≥ 2 137 (48%) 35 (50%) 102 (48%)  
- NC 78 (27%) 19 (26%) 59 (28%)  
Arterial hypertension      
- Yes 93 (33%) 39 (55%) 94 (44%) 0.28 
- No 133 (47%) 19 (27%) 74 (35%)  
- NC 58 (20%) 13 (18%) 45 (21%)  
Diabetes      
- Yes 47 (17%) 15 (21%) 32 (15%) 0.17 
- No 208 (73%) 46 (65%)  162 (76%)  
- NC 29 (10%) 10 (14%) 19 (9%)  
Menopausal hormone 
therapy  
    
- Yes 38 (13%) 5 (7%)  33 (16%) 0.19 
- No 133 (47%) 35 (49%) 98 (46%)   
- NC 113 (40%) 31 (44%) 82 (38%)  
NC: not communicated 
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Table 2: Tumour characteristics 
 
 
Characteristics 
 
Population n (%) 
N=284 
No lymphadenectomy 
 n (%) 
N = 71 
Lymphadenectomy 
n (%) 
N = 213 
P  
value 
Tumour size     
- < 3,5 cm 60 (21%) 14 (20%) 46 (22%) <0.001 
- ≥ 3,5 cm 116 (41%) 17 (24%)             99 (46%)  
- NC 
Tumour size  
-<1.5 cm 
-  ≥ 1.5cm 
-NC 
108 (38%) 
  
13 (5%) 
163 (57%) 
108 (38%) 
40 (56%) 
 
3 (4%) 
28 (40%) 
40 (56%) 
68 (32%) 
 
10 (5%) 
135 (63%) 
68 (32%) 
 
 
<0.001 
Myometrial invasion     
- < 50% 84 (30%) 27 (38%) 57 (27%) 0.10 
- ≥ 50% 182 (64%) 38 (54%) 144 (68%)  
- NC 18 (6%) 6 (8%) 12 (5%)  
Histology     
- Endometrioid 161 (57%) 35 (49%) 126 (59%) 0.31 
- Serous 43 (15%) 11 (16%) 32 (15%)  
- Clear cells 28 (10%) 8 (11%) 20 (10%)  
- Other *  49 (17%) 17 (24%) 32 (15%)  
- NC 3 (1%) 0 3 (1%)  
Histological type     
- Type 1 161 (57%) 35 (49%) 126 (59%) 0.24 
- Type 2 109 (38%) 31 (44%) 78 (37%)  
- Other** 13 (4%) 5 (7%) 8 (3%)  
- NC 1 (1%) 0 1 (1%)  
Histological grade      
- 1 54 (19%) 12 (17%) 42 (20%) 0.77 
- 2 72 (25%) 17 (24%) 55 (26%)  
- 3 153 (54%) 40 (56%) 113 (53%)  
- NC 5 (2%) 2 (3%) 3 (1%)  
Lymphovascular space 
involvement 
    
- Yes 167 (59%)  39 (55%) 128 (60%) 0.59 
- No 91 (32%) 25 (35%) 66 (31%)   
- NC 26 (9%) 7 (10%) 19 (9%)  
Pelvic lymph node metastasis 
(N =212) 
    
- Yes 44 (21%) - 45 (21%) NA 
- No 138 (65%) - 137 (64%)  
- NC 30 (14%) - 31 (15%)  
Para-aortic lymph node 
metastasis (N =25) 
   
 
 
- Yes 7 (28%) - 7 (28%) NA 
- No 18 (72%) - 18 (72%)  
- NC 0 - 0  
FIGO stage     
- I 124 (43%) 31 (44%) 93 (44%) 0.35 
- II 51 (18%)  14 (20%) 37 (17%)  
- III 98 (35%) 21 (29%)  77 (36%)  
- IV 11 (4%) 5 (7%) 6 (3%)  
ESMO/ESGO/ESTRO risk 
groups  
    
- High-intermediate risk 52 (18%) 13 (18%) 39 (18%)           0.12 
- High risk   
- Advanced 
220 (77%) 
12 (4%) 
52 (73%) 
6 (9%) 
168 (79%) 
6 (3%) 
 
      
     
NC: not communicated ; * mucineux, tubuleux, carcinosarcome, indifférentié ; **mucineux, tubuleux  
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Table 3: Surgical characteristics and adjuvant treatment  
 
 
Characteristics 
Population  
n (%)  
N=284 
No lymphadenectomy 
 n (%) 
N=71 
Lymphadenectomy 
n (%) 
N=213 
P  
value 
Surgical approach:     
- Laparoscopy 112 (39%) 14 (21%)  98 (46%)  <0.001 
- Laparotomy 128 (45%) 35 (49%) 93 (44%)  
- Vaginal approach 16 (6%) 11 (15%) 5 (2%)   
- NA 
 
28 (10%) 11 (15%)  17 (8%)  
Sentinel lymph node (N=213)     
- Yes 77 (36%) - 77 (36%) NA 
- No 82 (39%) - 82 (39%)  
- NA 
 
Sentinel lymph node metastasis 
(N=77) 
-Yes 
-No 
-NA 
 
Pelvic lymphadenectomy 
Paraaortic lymphadenectomy 
 
No. pelvic node removed, mean 
(±SD) 
54 (25%) 
 
 
 
 
 
 
 
212 (75%) 
25 (9%) 
 
11.90 (±6.19) 
- 54 (25%) 
 
 
 
                  35 (46%) 
24 (31%) 
18 (23%) 
 
212 (99%) 
25 (12%) 
 
11.90 (±6.19) 
 
 
No. paraaortic node removed, mean 
(±SD) 
       3.85 (±6.79)  3.85 (±6.79)  
                       
Adjuvant treatment  
No adjuvant therapy  
VBT alone  
EBRT +/- VBT  
Chemotherapy +/- EBRT  
EBRT 
 
56 (20%) 
41 (14%) 
128 (45%) 
59 (21%) 
164 (58%) 
 
 
 
 
19 (27%) 
9 (13%) 
28 (39%) 
15 (21%) 
32 (45%) 
 
 
 
 
37 (17%) 
32 (15%) 
100 (47%) 
44 (21%) 
132 (62%) 
                 
 
0.27 
 
* According to 2010 French guidelines NC: not 
communicated; NS: not significant; EBRT: External 
beam radiotherapy.   
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Table 4: Three-year disease-free survival, cancer-specific survival and overall survival rates (multivariate analysis) 
 
 
Characteristics 
 
 
Disease-free 
survival rate,  
% (95% CI)  
 
P 
Cancer-specific 
survival rate,  
% (95%CI)  
 
P 
Overall survival 
rate,  
% (95% CI)  
 
P 
Lymphadenectomy 
-Yes 
 
 
 
1 
  
          1 
  
            1 
 
 
-No 
 
Age:  
-<75 years 
-76-80 years 
-81-85 years 
-≥86 years 
 
Histology 
-type1 
-type 2 
 
Lymphovascular space 
involvement 
-No 
-Yes 
 
ESMO/ESGO/ESTRO 
risk groups  
-HR 
-HIR 
 
Lymph node metastasis 
-No 
-Yes  
- Node status unknown 
(Lymphadenectomy not 
performed) 
 
Adjuvant treatment:  
- Chemotherapy +/- EBRT 
-No adjuvant therapy  
-VBT alone  
-EBRT +/- VBT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.939 (0.36-2.46) 
 
 
1 
1.072 (0.64-1.81) 
0.733 (0.34-1.59) 
1.059 (0.30-3.69) 
 
 
1 
1.409 (0.85-2.34) 
 
 
 
1 
2.216 (1.22-4.03) 
 
 
 
1 
0.808 (0.39-1.69) 
 
 
1 
0.848 (0.45-1.59) 
1.713 (0.68-4.31) 
 
 
 
 
1 
0.84 (0.38-1.85) 
0.227 (0.08-0.66) 
0.646 (0.36-1.15) 
 
 
 
 
 
  
0.897 
 
 
 
0.792 
0.434 
0.929 
 
 
 
0.185 
 
 
 
 
0.009 
 
 
 
 
0.569 
 
 
 
0.609 
0.253 
 
 
 
 
 
0.666 
0.006 
0.139 
 
 
 
 
 
 
 
3.027 (1.58-5.81) 
 
 
1 
1.196 (0.52-2.75) 
0.592 (0.19-1.85) 
1.57 (0.4-4.19) 
 
 
1 
3.466 (1.51-7.97) 
 
 
 
1 
3.477 (1.35-8.98) 
 
 
 
1 
0.713 (0.21-2.43) 
 
 
1 
1.103 (0.41-2.95) 
2.269 (1.02-5.03) 
 
 
 
 
1 
2.023 (0.63-6.51) 
0.417 (0.08-2.23) 
1.321 (0.52-3.33) 
 
 
 
 
<0.001 
 
 
 
0.673 
0.368 
0.519 
 
 
 
0.003 
 
 
 
 
0.01 
 
 
 
 
0.588 
 
 
 
0.846 
0.044 
 
 
 
 
 
0.238 
0.307 
0.555 
2.374 (1.48-3.81) 
 
 
1 
1.013 (0.54-1.91) 
0.556 (0.23-1.33) 
1.193 (0.38-3.75) 
 
 
1 
2.256 (1.23-4.13) 
 
 
 
1 
3.165 (1.56-6.43) 
 
 
 
1 
0.839 (0.36-1.96) 
 
  
1 
1.629 (0.84-3.15) 
2.389 (1.32-4.34) 
 
 
 
 
1 
1.26 (0.54-2.95) 
0.309 (0.09-1.01) 
0.854 (0.43-1.68) 
 
 
 
 
 
 
 
<0.001 
 
 
 
0.967 
0.185 
0.763 
 
 
 
0.008 
 
 
 
 
0.001 
 
 
 
 
0.685 
 
 
 
0.147 
0.004 
 
 
 
 
 
0.593 
0.053 
0.648 
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Table S1: Three-year disease-free survival, cancer-specific survival and overall survival rates (univariate analysis) 
 
 
Characteristics 
Disease-free 
survival rate, 
% (95% CI)  
 
P 
Cancer-specific 
survival rate, 
% (95%CI)  
 
P 
Overall survival 
rate, 
% (95% CI)  
 
P 
Population  67.4% (60.8-74.6)  81.3% (75.5-87.6)  66.8% (60-74.4)  
Lymphadenectomy:  
-Yes 
 
70.94% (63.7-79) 
 
0.076 
 
85.2% (78.9-92.1) 
 
<0.001 
 
71.6% (64.07-80) 
 
<0.001 
-No 
 
Age:  
-76-80 years 
-81-85 years 
-≥86 years 
 
Histology:  
-type1 
-type 2 
 
Lymphovascular space 
involvement:  
-Yes 
-No 
 
ESMO/ESGO/ESTRO 
risk groups:  
-HIR 
-HR 
 
Lymph node metastasis 
N=213 
-Yes 
-No  
- Node status unknown 
(Lymphadenectomy not 
performed) 
 
Adjuvant treatment:  
-No adjuvant therapy  
-VBT alone  
-EBRT +/- VBT  
-Chemotherapy +/- EBRT  
56.35% (43.4-73.3) 
 
 
68.7% (58-81.5) 
66.3% (49.8-88.2) 
78.3% (59.2-100) 
 
 
70.8% (62.7-79.9) 
61.53% (51.1-74.1) 
 
 
 
61.49% (52.9-71.5) 
78.7% (68.7-90.1) 
 
 
 
74.2% (60.6-90.9) 
65.68% (58.4-73.9) 
 
 
 
69.69% (56.7-85.7) 
73.8% (63.7-85.5) 
53.12% (40.9-68.9) 
 
 
 
 
67.7% (52.6-87.1) 
86.8% (75.3-100) 
68.13% (59-78.7) 
54.8% (41.2-72.8) 
 
 
 
 
 
 
0.96 
 
 
 
 
0.26 
 
 
 
 
0.02 
 
 
 
 
0.31 
 
 
 
 
0.082 
 
 
 
 
 
 
0.003 
 
 
 
67.5% (54.8-83.1) 
 
 
81.1% (70.9-92.8) 
75% (58.6-96.1) 
54% (27-100) 
 
 
84.8% (77.3-92.9) 
72.2% (62-84.2) 
 
 
 
75.7% (67.5-84.9) 
86.8% (76.7-98.2) 
 
 
 
86.6% (74.7-100) 
78.8% (72-86.3) 
 
 
 
74.8% (60.2-92.8) 
83.1% (73.7-93.6) 
74.8% (64.2-87.1) 
 
 
 
 
69.9% (52.2-93.5) 
86.5% (68.3-100) 
79.3% (70.9-88.7) 
82.9% (71.9-95.5) 
 
 
 
 
 
 
 
 
0.51 
 
 
 
 
0.009 
 
 
 
 
0.03 
 
 
 
 
0.1 
 
 
 
 
0.121 
 
 
 
 
 
 
0.112 
 
 
 
 
 
 
50.2% (36.9-68.2) 
 
 
63.7% (52.2-77.9) 
63% (46.4-85.5) 
60% (35.1-100) 
 
 
71.3% (62.9-80.9) 
59.4% (48.7-72.4) 
 
 
 
62.4% (53.6-72.7) 
71% (58.9-85.6) 
 
 
 
77.6% (63.7-94.4) 
64.4% (56.8-72.9) 
 
 
 
61.7% (46.9-81) 
76.2% (66.1-87.9) 
59.7% (47.2-75.4) 
 
 
 
 
54.6% (38.1-78.3) 
89% (77.8-100) 
69.1% (59.5-80.3) 
50.5% (36.2-70.3) 
 
 
 
0.56 
 
 
 
 
0.03 
 
 
 
 
0.1 
 
 
 
 
0.12 
 
 
 
 
0.015 
 
 
 
 
 
 
0.002 
 
 
 
CI: confidence interval 
 
 
 
 
